Tregs were increased and activated in DTC tumor tissue, indicating that they play an important role in creating an immunosuppressive microenvironment in DTC. The results suggest that eTreg-depletion immunotherapy using an anti-CCR4 antibody (mogamulizumab) might be effective for treating DTC.

Our study provides novel insights into the molecular properties of residual malignant clones within MAR that appear silenced, surrounded by a putatively anti-tumor immune response.

LMR is a novel prognostic factor in r/r ATL and may provide useful information when considering mogamulizumab-based treatment.

The effects of mogamulizumab and chemical antagonists of C-C/C-X-C chemokine receptors TAK-799, SB225002, and MK-7123 on SCI recovery in rodents are further estimated. Here blockade of CCR5 and CXCR1/2 chemokine receptors is shown beneficial for amelioration of acute SCI, whereas anti-CCR4 antibody mogamulizumab readily prevents secondary inflammation in the injured area. Summarizing, the current report claims for a novel combined time-resolved therapeutic modality in SCI treatment, which supports feasibility and motivates off-label clinical evaluation in appropriate cohorts.

P2, N=34, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Jun 2028 | Trial primary completion date: Jan 2026 --> Jun 2028

P4, N=23, Active, not recruiting, Kyowa Kirin China Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting

Monoclonal antibodies or antibody-drug conjugates targeting T-cell lymphoma surface antigens have been approved, including brentuximab vedotin, for the treatment of CD30-positive nodal and cutaneous T-cell lymphoma, and mogamulizumab, for mycosis fungoides and adult T-cell leukaemia/lymphoma. Novel approaches including cell therapy and adoptive immunotherapy are currently being evaluated. In this Series paper, we discuss the limitations of the conventional treatment options and the use of these novel approaches for mature T-cell and natural killer-cell lymphomas.

No significant adverse effects of valemetostat were observed early after transplantation, in contrast to the increased incidence of severe GVHD and non-relapse mortality reported following allo-HCT after mogamulizumab therapy. These findings suggest that valemetostat is a promising option as a bridging therapy to allo-HCT for aggressive ATL.

P=N/A, N=15, Recruiting, Kyowa Kirin Co., Ltd.

These findings suggest a potential beneficial effect of Romi-Moga therapy when administered in close sequence. Prospective studies are needed to validate these results and optimize treatment strategies.